| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 09/16/1999 | CA2323236A1 Human receptor proteins; related reagents and methods |
| 09/16/1999 | CA2323210A1 Enhancement of intracellular delivery and tissue targeting of drugs and genes |
| 09/16/1999 | CA2323109A1 Ribozymes capable of inhibiting the expression of the ccr5 receptor |
| 09/16/1999 | CA2323074A1 Compositions and methods for the treatment and prevention of metastatic disorders |
| 09/16/1999 | CA2323069A1 Nucleic acid enzyme showing allosteric rna-cleaving activity on target rna |
| 09/16/1999 | CA2323067A1 Producer cells for replication selective viruses in the treatment of malignancy |
| 09/16/1999 | CA2322748A1 Vascular endothelial growth factor 2 |
| 09/16/1999 | CA2322728A1 31 human secreted proteins |
| 09/16/1999 | CA2322663A1 Induction of apoptotic or cytotoxic gene expression by adenoviral mediated gene codelivery |
| 09/16/1999 | CA2322508A1 Modified factor viii |
| 09/16/1999 | CA2322232A1 Lyophilized polynucleotide composition, method of preparation, and uses thereof |
| 09/15/1999 | EP0942000A2 2'Modified oligonucleotides |
| 09/15/1999 | EP0941364A1 Process aimed at evidencing the state of a malignant cell and process for treatment |
| 09/15/1999 | EP0941356A2 Stabilized transient gene expression |
| 09/15/1999 | EP0941355A1 Recombinant bicistron adenovirus for treating pathological conditions linked with dyslipoproteinemia |
| 09/15/1999 | EP0941354A1 Syndecan enhancer element and its use for targeting gene expression |
| 09/15/1999 | EP0941342A1 Human squalene epoxidase |
| 09/15/1999 | EP0941341A1 Nucleotide sequence coding for a flavin-containing monooxygenase, corresponding protein and their applications in the fields of diagnosis and therapy |
| 09/15/1999 | EP0941339A1 Therapeutic gene |
| 09/15/1999 | EP0941336A2 Papilloma viruses, agents for detecting the same and for treating diseases caused by such viruses |
| 09/15/1999 | EP0941335A2 Streptococcus pneumoniae polynucleotides and sequences |
| 09/15/1999 | EP0941330A1 Therapeutic compositions and methods for treating disease states with myeloid progenitor inhibitory factor-1 (mpif-1), monocyte colony inhibitory factor (m-cif), and macrophage inhibitory factor-4 (mip-4) |
| 09/15/1999 | EP0941329A1 Methods for preventing graft rejection in transplantation and for producing a universal gene therapy host cell using lymphocyte activation (lag-3) |
| 09/15/1999 | EP0941328A1 Human breast tumor-specific proteins |
| 09/15/1999 | EP0941327A1 Human g-protein receptor hcegh45, a pacap-like (g-protein pituitary adenylate cyclase activating polypeptide-like) receptor |
| 09/15/1999 | EP0941326A1 Murine guanine nucleotide exchange factor (mngef) and human homologues thereof |
| 09/15/1999 | EP0941321A1 Circularly permuted polypeptides as novel stem cell factor receptor agonists |
| 09/15/1999 | EP0941318A1 Design principle for constructing expression constructs for gene therapy |
| 09/15/1999 | EP0941317A1 Insulin-like growth factor 1 receptor (igf-1r) antisense oligonucleotide-treated breast cancer cells composition |
| 09/15/1999 | EP0941307A1 Use of flexible plastic tanks in gene theraphy |
| 09/15/1999 | EP0941252A1 Anti-p53 single-chain antibody fragments and their uses |
| 09/15/1999 | EP0941245A1 Promoter for smooth muscle cell expression |
| 09/15/1999 | EP0941243A1 Polypeptides comprising gax protein domains, involved in repressing transcription and/or interacting with other proteins, corresponding nucleic acids and their use |
| 09/15/1999 | EP0941242A2 Secreted proteins and polynucleotides encoding them |
| 09/15/1999 | EP0941239A1 Vertebrate homologues of unc-53 protein of c. elegans |
| 09/15/1999 | EP0941234A1 Preprotachykinin-c gene encoding substance z tachykinin precursor |
| 09/15/1999 | EP0941125A1 Methods for regulating angiogenesis |
| 09/15/1999 | EP0941124A1 Antisense oligonucleotide compositions for selectively killing cancer cells |
| 09/15/1999 | EP0941123A2 Delivery of nucleic acid material to target cells in biological systems |
| 09/15/1999 | EP0941122A2 Compositions and methods for polynucleotide delivery |
| 09/15/1999 | EP0941116A2 Therapeutic use of an agent that stimulates no or prostacyclin production and delivery device |
| 09/15/1999 | EP0941109A1 Pretreatment with growth factors to protect against cns damage |
| 09/15/1999 | EP0941108A1 Wound healing and treatment of fibrosis |
| 09/15/1999 | EP0941066A1 Cationic lipid-nucleic acid complexes |
| 09/15/1999 | EP0776335A4 Regulatable elimination of gene expression, gene product function and engineered host cells |
| 09/15/1999 | EP0748383B1 Targeted cleavage of rna using ribonuclease p targeting and cleavage sequences |
| 09/14/1999 | US5952488 A nucleic acid molecule containing an androgen response element linked to a reporter gene; diagnosis and therapy for prostatic diseases and cancer |
| 09/14/1999 | US5952483 Human IκB-β |
| 09/14/1999 | US5952311 Photosensitizing chemical means for killing tumor cells, wherein tumoricidal activity is activated by absorbing light or energy within a specific wavelength range, and energy donating chemical means for activating photosensitizer |
| 09/14/1999 | US5952232 Expandible microparticle intracellular delivery system |
| 09/14/1999 | US5952226 Hypoxia responsive EPO producing cells |
| 09/14/1999 | US5952225 A packaging cell containing a polynucleotide which codes a portion of a selected retrovirus having at least the envelope protein; for producing vectors resistant to complement inactivation by serum; gene therapy |
| 09/14/1999 | US5952221 A virion having a drug-sensitivity gene and a second gene capable of providing ancillary effects to solid tumor cells; gene therapy and antitumor agents |
| 09/14/1999 | US5952220 Preparing a dilute viral suspension in an aqueous solution which is then nebulised with gas pressure or ultrasound; treatment of respiratory diseases, asthma, lung cancer, cystic fibrosis |
| 09/14/1999 | US5952190 A nucleic acid molecule, that when expressed in transfected cells from patients, is able to complement the hypersensitivity to mitomycin c; diagnosis and screening of fanconi anemia; gene therapy |
| 09/14/1999 | US5951976 Vaccinating a mammal by administering a composition comprising an opsonin-enhanced cell comprising said selected antigen with the provision the opsonin does not bind to a receptor for a fragment of c33 |
| 09/14/1999 | US5951975 Immunization with a foreign artificial target antigen to promote a cytotoxic t-lymphocyte response; loading cultured tumor cells with antigen; deactivating the cells; immunizing with the cell to get a response to unmodified tumor |
| 09/14/1999 | CA2071446C Synthetic catalytic oligonucleotide structures |
| 09/10/1999 | WO1999045135A1 Novel fdrg protein and nucleic acid molecules and uses therefor |
| 09/10/1999 | WO1999045132A1 Poly zinc finger proteins with improved linkers |
| 09/10/1999 | WO1999045127A2 Enhanced prodrug activation |
| 09/10/1999 | WO1999045126A2 Enhanced prodrug activation |
| 09/10/1999 | WO1999045113A1 Smad binding elements and uses thereof |
| 09/10/1999 | WO1999045112A2 Chromosome 11-linked coronary heart disease susceptibility gene chd1 |
| 09/10/1999 | WO1999045108A2 Novel mechanically sensitive mammal potassium channel family activated by polyunsaturated fatty acids and their use particularly for screening medicines |
| 09/10/1999 | WO1999045098A2 Delivery or proteins into eukaryotic cells with recombinant yersinia |
| 09/10/1999 | WO1999044943A2 Vectors and viruses used in gene therapy |
| 09/10/1999 | WO1999044656A1 Minimally invasive gene therapy delivery device and method |
| 09/10/1999 | WO1999044645A1 Compositions and methods of treating tumors |
| 09/10/1999 | WO1999044644A1 Improved eukaryotic expression vector |
| 09/10/1999 | WO1999044633A1 Live recombined vaccines injected with adjuvant |
| 09/10/1999 | WO1999044629A2 Utilization of cd137 in order to promote the proliferation of peripheral monocytes |
| 09/10/1999 | WO1999044625A1 Smallpox inhibitor of complement enzymes (spice) protein and methods of inhibiting complement activation |
| 09/10/1999 | WO1999044423A1 Amplification of gene transfer and gene therapy by controlled replication |
| 09/10/1999 | WO1999035255A8 Compositions and methods for regulated secretion from neuroendocrine cell lines |
| 09/10/1999 | WO1999032514A3 Sag: sensitive to apoptosis gene |
| 09/10/1999 | WO1999031262A3 Needle-free injection of formulated nucleic acid molecules |
| 09/10/1999 | WO1999028489A9 Cell-specific retroviral vectors with antibody domains and method for the production thereof for selective gene transfer |
| 09/10/1999 | WO1999028466A9 Compositions and methods of use of het |
| 09/10/1999 | WO1999027958A9 Hiv-1 tat, or derivatives thereof for prophylactic and therapeutic vaccination |
| 09/10/1999 | WO1999027102A9 Cd4+ t-lymphocyte protease genes and inhibitors thereof |
| 09/10/1999 | WO1999025829A3 Cdk2 protein and cdk2 protein complexes |
| 09/10/1999 | WO1999025819A3 Antisense oligonucleotides against tenascin for treating vitiligo |
| 09/10/1999 | WO1999021992A3 Nucleic acid molecules encoding a glutamate receptor |
| 09/10/1999 | WO1999020644A9 Secreted proteins and polynucleotides encoding them |
| 09/10/1999 | WO1998005356A8 NOVEL FtsL |
| 09/10/1999 | CA2322786A1 Minimally invasive gene therapy delivery device and method |
| 09/10/1999 | CA2322684A1 Utilization of cd137 in order to promote the proliferation of peripheral monocytes |
| 09/10/1999 | CA2322665A1 Delivery of proteins into eukaryotic cells with recombinant yersinia |
| 09/10/1999 | CA2322664A1 Enhanced prodrug activation |
| 09/10/1999 | CA2322592A1 Use of a peptide or antibody in the manufacture of a medicament for treating an erbb protein medicated tumor in combination with irradiation |
| 09/10/1999 | CA2322425A1 Novel fdrg protein and nucleic acid molecules and uses therefor |
| 09/10/1999 | CA2249661A1 Novel compounds |
| 09/10/1999 | CA2249041A1 Novel compounds |
| 09/09/1999 | DE19808889A1 Vektoren und Viren zur Gentherapie Vectors and viruses for gene therapy |
| 09/08/1999 | EP0940467A1 Promoters for swine complement inhibitors |
| 09/08/1999 | EP0939832A1 Mitochondrial dna mutations that segregate with late onset diabetes mellitus |
| 09/08/1999 | EP0939828A1 Herpesvirus saimiri as viral vector |
| 09/08/1999 | EP0939827A1 Lentiviral vectors |
| 09/08/1999 | EP0939823A1 Genes encoding telomerase proteins |